Company Overview and News

94
10 Consumer Stocks on the Clearance Rack

2018-06-19 investorplace
U.S. equities are trading meekly on Monday, inching lower with caution. The specter of an outright trade war with China looms large, with a tit-for-tat involving billions in import tariffs already underway. Moreover, central banks are turning increasingly hawkish with the Federal Reserve jacking interest rates higher again last week and promising two more hikes before the year is out. The European Central Bank is committed to ending its bond buying stimulus program before the end of the year.
PM GIS HSYFB PG KMB KCDMY HRL KMB.WI CL KO CLX HSY MO

40
CL / Colgate-Palmolive Co. COLGATE-PALMOLIVE COMPANY 8-K (Current Report)

2018-06-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CL

228
10 Best Stocks to Buy and Hold Forever

2018-06-15 investorplace
In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place.
SOJA SO MTSI AWK TWX GOOG WM TWC WMT BRK.A AMZN T CL JNJ GOOGL MMM

40
CL / Colgate-Palmolive Co. COLGATE-PALMOLIVE COMPANY 11-K 12-31-2017

2018-06-14 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CL

87
5 Consumer Staples Stocks to Buy for Long-Term Gains | InvestorPlace

2018-06-13 investorplace
For conservative investors, consumer staples have often been a great go-to sector for defense and a hefty dose of dividends. The reason is simple — no matter what the economy is doing, you still need to brush your teeth, do laundry and go to the bathroom. Because of this steady nature, consumer staples typically offer low, but predictable growth, cash flows and large dividend yields.
EL CL MKC KO FIZZ RB CLX WMT

74
Cisco Is A High Quality Stock - Cramer's Lightning Round (6/8/18)

2018-06-11 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, June 8.
MGM MAT HAS OSK PEP CL CSCO UTX COL

40
CL / Colgate-Palmolive Co. null

2018-05-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD
CL

138
For Now It’s Best to Avoid Colgate-Palmolive Company Stock

2018-05-31 investorplace
The relative decline of Colgate-Palmolive Company (NYSE:CL) and its peers appears to have paused. Wall Street shrugged off news about the recall of Colgate’s Orabase and competing products. Now, Wall Street analysts have turned bullish on CL stock, as profit growth seems to have returned.
PG AMZN KMB.WI CL UN KMB KCDMY

370
Consumer Products Aren’t Nearly as Safe as You Thought — They’re Dying

2018-05-27 investorplace
Broad markets so far this year have been relatively choppy, particularly since late January peaks. But that hasn’t been the case for large-cap consumer stocks.
PM GIS PG BTI ULVR CPB MNST BATS 4162 FIZZ CHD UNLNF WMT DLTR TSNU KR AMZN CL MKC KO CAG TSN HSY MO BUD SHOP HSYFB UL SJM UN UNLYF MDLZ K BRK.A HRL BREW KHC DG CLX COTY

40
Colgate Palmolive (India) Limited - Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CL CLGQY

40
Colgate Palmolive (India) Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CL CLGQY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to CL / Colgate-Palmolive Co. on message board site Silicon Investor.

Classic TA Workplace Ratu0027s Nest - Chronicles of Collapse
Drones, Autonomous Vehicles and Flying Cars Clown-Free Zone... sorry, no clowns allowed
Research Frontiers Lonely Hearts Club Thread. [email protected] HotStove Club
Cloud, edge and decentralized computing Severe weather events, climate change and economics
Full Disclosure Trading Hillary Clinton 2016
CUSIP: 194162103